Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics develops gene therapy and antisense therapies targeting rare genetic diseases, with particular depth in muscular dystrophies and other neuromuscular disorders. The company has moved beyond pure research into commercialization: it has marketed products in hand, late-stage trials underway, and a platform approach—exon-skipping technology—that can potentially address dozens of different genetic mutations. The stock trades on NASDAQ under SRPT.

The science: exon-skipping as a platform

Sarepta’s core innovation is exon-skipping technology. Here is the problem it solves: many genetic diseases, particularly muscular dystrophies, arise because a mutation in a gene disrupts the reading frame, producing a nonfunctional protein. Duchenne muscular dystrophy, the severe childhood form, typically results from a large deletion in the dystrophin gene. The mutation is so disrupting that the gene cannot make any useful protein, and the disease is devastating.

Exon-skipping is a molecular workaround. Instead of trying to fix the mutation itself, Sarepta’s therapies tell the cell’s protein-synthesis machinery to skip over the damaged section of the gene, allowing the cell to read through and produce a shortened but functional protein. For Duchenne, that shortened dystrophin is not full-length, but it is enough to provide meaningful therapeutic benefit—slowing muscle deterioration, preserving function, extending independence.

The beauty of the platform is that it scales. Each dystrophy or genetic disease is caused by different mutations, but the same exon-skipping logic applies to many of them. Sarepta has built a platform to design and test exon-skipping drugs systematically, which means the company can pursue multiple indications and potentially add new ones if clinical opportunity emerges.

Products in the market and the pipeline

Sarepta’s flagship approved product, exondys51, is an exon-skipping therapy for Duchenne muscular dystrophy. It was approved by the FDA in 2016 through an accelerated pathway based on promising early data, and it has since been used by patients with certain forms of the disease. A second-generation therapy, delandistrogene moxeparvovec, represents a more ambitious approach: rather than repeated infusions of exon-skipping oligonucleotides, this is a gene therapy using a viral vector to deliver the therapeutic gene directly into muscle tissue, offering the possibility of a one-time treatment.

Beyond Duchenne, Sarepta is pursuing exon-skipping approaches in other muscular dystrophies—Limb-Girdle muscular dystrophy, facioscapulohumeral dystrophy, and others—each rare but with dedicated patient populations and unmet medical need. The company has also expanded into non-dystrophy areas, such as certain eye diseases, broadening its addressable market.

The commercial landscape for rare genetic diseases is favorable in some ways and challenging in others. Patient populations are small, so total sales for any single indication will never be blockbuster-scale. But regulatory pathways are streamlined—accelerated approvals, breakthrough designations, orphan-drug incentives—and payers tend to reimburse rare disease treatments generously if clinical benefit is clear. The risk is that clinical trials fail, the expected benefit does not materialize, or a rival therapy emerges and proves superior.

The business model and capital requirements

Sarepta is a development-stage biotech company with approved products generating revenue but a balance sheet shaped by R&D spending. Gene therapies are expensive to develop: preclinical work, clinical trials for rare diseases with small patient populations, manufacturing of viral vectors or synthetic oligonucleotides, and regulatory navigation. The company has needed to fund this through a combination of public stock offerings, debt, and partnership deals with larger pharma companies that see value in the platform.

Revenue from approved products helps offset burn, but until the company reaches sustainable profitability—if it does—share price and access to capital markets are existential concerns. Biotech investors price in the risk that a key trial fails or a product underperforms expectations. Sarepta’s stock is thus far more volatile than a established pharmaceutical company, and it is sensitive to trial readouts, regulatory decisions, and partnership announcements.

Competitive landscape and risks

Sarepta is not alone in pursuing gene therapy for muscular dystrophies. Larger pharmaceutical companies and smaller biotech competitors are developing rival approaches—different gene therapies, different exon-skipping platforms, antisense drugs targeting related mechanisms. Clinical trial readouts and real-world efficacy data will determine the winners. A competitor’s therapy that proves significantly more effective, safer, or easier to administer could displace Sarepta’s products from the market.

Regulatory risk is real. The FDA approved exondys51 under accelerated pathways with the expectation that subsequent data would confirm benefit. If follow-up studies fail to show the expected clinical impact, regulators could restrict use or require additional evidence, which would damage commercial prospects and investor confidence.

Manufacturing and supply-chain reliability is another risk. Gene therapies, especially viral vector-based therapies, are complex to manufacture. Any production bottleneck, contamination, or quality issue could limit the company’s ability to supply patients and damage its reputation.

How to research Sarepta

The starting point is the 10-K filing (SEC CIK 0000873303), which details approved products, revenue, R&D spending, and pipeline programs. Earnings calls provide quarterly updates on patient enrollment in trials, revenue from approved products, and management commentary on competitive dynamics.

Clinical-trial tracking is essential: watch for readouts from late-stage programs, which are the primary drivers of long-term value. The FDA’s stance on accelerated approvals and regulatory pathways for gene therapies will influence the company’s development strategy. Also track partnerships or licensing deals—in biotech, a deal often signals management’s confidence in a program or need for capital. As with any individual security, Sarepta’s shares trade at prices set by the market, and nothing here is investment guidance.